^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD22 positive

    i
    Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
    Entrez ID:
    933
    Related biomarkers:
    Expression
    4d
    Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial. (PubMed, Lancet Haematol)
    Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths.
    P2 data • Journal
    |
    CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • Defitelio (defibrotide)
    7d
    Ph- ALL-2026: Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine
    14d
    Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Hrain Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> May 2027
    Enrollment closed • Trial completion date
    |
    CD22 (CD22 Molecule) • IL15 (Interleukin 15)
    |
    CD22 positive
    |
    anti-CD19/CD22 CAR-T cells
    1m
    CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Liping Dou
    New P2 trial
    |
    TP53 (Tumor protein P53) • CD22 (CD22 Molecule) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    TP53 mutation • CD22 positive
    1m
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    1m
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    1m
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    2ms
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Beijing Tongren Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    2ms
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: May 2028 --> May 2029 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    clonoSEQ®
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
    2ms
    ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=83, Recruiting, AstraZeneca
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    3ms
    A041703: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute (NCI) | N=64 --> 84
    Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    3ms
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (clinicaltrials.gov)
    P2, N=30, Recruiting, Daihong Liu
    New P2 trial
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule)
    |
    TP53 mutation • CD22 positive
    |
    Epidaza (chidamide)